Now that full data is out on brilacidin it's game
Post# of 72440
The pace very well could pick up. I know I'll be a happy camper once this is off the OTC.
Some may disagree, but IMO P results due out soon is pretty much a lock for excellent effectiveness and safety.
I'm also along the same thinking.
The dermatology space is huge. If they can infiltrate the various indications in the market, each one has its own reward, may take some time but the light is growing brighter. Just need that first starting point. I was giving more weight to the cancer indications for brilacidin.
Quote:
I agree that our potential is staggering in multiple revenue streams. I also believe it is a fair statement to say at this point in time that B appears to be a winner in all areas tested to date and most likely the dermatological applications will also follow suit. I think the dermatology related revenues could be on a par w/ OM, Psoriasis, and ABSSSI combined while IBD is very large and I have no current clue as to overall yearly potential.
Some may disagree, but IMO P results due out soon is pretty much a lock for excellent effectiveness and safety.
All in all, things couldn't be better though the FUDsters would lead one to believe everything going to hell in a hand basket. I really feel sorry for those that only know the other board as an IPIX news source since they get dismal predictions 24/7.
Does seem to be rubbing the FUDsters raw that Leo apparently has chosen not to put out any news on the unblinding of P data.
The clock is ticking fudsters. Better start working on your Go Fund Me profiles.